Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis [Phase 3]

View source ↗

Summary

This clinical trial update notes that oral Nizubaglustat (AZ-3102) is being studied in a Phase 3 trial for late-infantile and juvenile Niemann-Pick disease type…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm1 Gangliosidosis
• Gm2 Gangliosidosis
• Niemann-pick Disease Type

Drugs mentioned

• Nizubaglustat

Snippet

Sponsor: Azafaros A.G. | Conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis | Phase 3 | Status: RECRUITING